Literature DB >> 23890557

Vitamin D in thyroid tumorigenesis and development.

Isabelle Clinckspoor1, Lieve Verlinden, Chantal Mathieu, Roger Bouillon, Annemieke Verstuyf, Brigitte Decallonne.   

Abstract

Besides its classical role in bone and calcium homeostasis, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D, has many non-classical effects; antiproliferative, anti-apoptotic and prodifferentiating effects of 1,25(OH)2D3 have been described in several tumour types in preclinical models. This review focuses on the insights gained in the elucidation of the role of 1,25(OH)2D3 in the normal thyroid and in the pathogenesis, progression and treatment of thyroid cancer, the most common endocrine malignancy. An increasing amount of observations points towards a role for impaired 1,25(OH)2D3-VDR signalling in the occurrence and progression of thyroid cancer, and a potential for structural analogues in the multimodal treatment of dedifferentiated iodine-resistant thyroid cancer. A role for vitamin D in thyroid-related autoimmunity is less convincing and needs further study. Altered 1,25(OH)2D3-VDR signalling does not influence normal thyroid development nor thyrocyte function, but does affect C-cell function, at least in rodents. If these findings also apply to humans deserves further study.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  1,25(OH)(2)D(3); 1α,25-dihydroxyvitamin D(3); 1α-hydroxylase; 24-hydroxylase; 25-OHD(3); 25-hydroxyvitamin D(3); ATC; CDK; CDKI; CEA; CT; CYP24A1; CYP27B1; DBP; DC; DIT; DTC; Duox; ER; FA; FGF23; FNAC; FTC; G-protein coupled receptor; GPCR; H&E; H(2)0(2); HAT; HDAC; HDACI; HPT; I-Tg; KO; MIT; MTC; NIS; PDS; PDTC; PMCA; PPI; PTC; PTH; RT-PCR; RXR; Rb; SAHA; T3; T4; TH; TKI; TPO; TRH; TSH; TSHR; Tg; US; VDR; VDRE; VEGF; WT; anaplastic thyroid cancer; calcitonin; carcinoembryogenic antigen; cyclin-dependent kinase; cyclin-dependent kinase inhibitor; dendritic cells; differentiated thyroid cancer; diiodotyrosine; dual oxidase; estrogen receptor; fibroblast growth factor-23; fine needle aspiration cytology; follicular adenoma; follicular thyroid cancer; haematoxylin and eosin; histone acetyltransferase; histone deacetylase; histone deacetylase inhibitor; hydrogen peroxide; hypothalamic-pituitary-thyroid; iodinated thyroglobulin; knockout; medullary thyroid cancer; monoiodotyrosine; papillary thyroid cancer; parathormone; pendrin; plasma membrane calcium ATPase; poorly differentiated thyroid cancer; proton pump inhibitor; retinoblastoma; retinoid X receptor; reverse transcriptase–polymerase chain reaction; sodium iodide symporter; suberoylanilide hydroxamic acid; thyroglobulin; thyroid hormone; thyroid peroxidase; thyroid stimulating hormone; thyroid stimulating hormone receptor; thyrotropin releasing hormone; thyroxine; tri-iodothyronine; tyrosine kinase inhibitor; ultrasound; vascular endothelial growth factor; vitamin D binding protein; vitamin D receptor; vitamin D responsive element; wild type.

Mesh:

Substances:

Year:  2013        PMID: 23890557     DOI: 10.1016/j.proghi.2013.07.001

Source DB:  PubMed          Journal:  Prog Histochem Cytochem        ISSN: 0079-6336


  19 in total

1.  Vitamin D receptor and progesterone receptor protein and gene expression in papillary thyroid carcinomas: associations with histological features.

Authors:  M P Yavropoulou; G Panagiotou; K Topouridou; G Karayannopoulou; T Koletsa; T Zarampoukas; A Goropoulos; E Chatzaki; J G Yovos; K Pazaitou-Panayiotou
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

Review 2.  Vitamin D and thyroid disease: to D or not to D?

Authors:  G Muscogiuri; G Tirabassi; G Bizzaro; F Orio; S A Paschou; A Vryonidou; G Balercia; Y Shoenfeld; A Colao
Journal:  Eur J Clin Nutr       Date:  2014-12-17       Impact factor: 4.016

3.  VITAMIN D LEVEL AND ITS RELATIONSHIP WITH CANCER STAGE IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA.

Authors:  A M Cocolos; S Vladoiu; A Caragheorgheopol; A M Ghemigian; D Ioachim; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

4.  Vitamin D-neutralizing CYP24A1 expression, oncogenic mutation states and histological findings of human papillary thyroid cancer.

Authors:  B Balla; B Tobiás; J P Kósa; J Podani; P Horváth; Z Nagy; J Horányi; B Járay; E Székely; L Krenács; K Árvai; M Dank; Z Putz; B Szabó; B Szili; Z Valkusz; B Vasas; G Győri; P Lakatos; I Takács
Journal:  J Endocrinol Invest       Date:  2014-09-09       Impact factor: 4.256

Review 5.  Insights into genetic and epigenetic determinants with impact on vitamin d signaling and cancer association studies: the case of thyroid cancer.

Authors:  Grégoire B Morand; Sabrina Daniela da Silva; Michael P Hier; Moulay A Alaoui-Jamali
Journal:  Front Oncol       Date:  2014-11-04       Impact factor: 6.244

6.  Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease.

Authors:  Yun Mi Choi; Won Gu Kim; Tae Yong Kim; Sung Jin Bae; Hong-Kyu Kim; Eun Kyung Jang; Min Ji Jeon; Ji Min Han; Young Kee Shong; Won Bae Kim
Journal:  Korean J Intern Med       Date:  2016-09-01       Impact factor: 2.884

Review 7.  Sunshine vitamin and thyroid.

Authors:  Immacolata Cristina Nettore; Luigi Albano; Paola Ungaro; Annamaria Colao; Paolo Emidio Macchia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

8.  No Association between 25 (OH) Vitamin D Level And Hypothyroidism among Females.

Authors:  Imad R Musa; Gasim I Gasim; Sajjad Khan; Ibrahim A Ibrahim; Hamdi Abo-Alazm; Ishag Adam
Journal:  Open Access Maced J Med Sci       Date:  2017-03-19

9.  Physiological serum 25-hydroxyvitamin D concentrations are associated with improved thyroid function-observations from a community-based program.

Authors:  Naghmeh Mirhosseini; Ludovic Brunel; Giovanna Muscogiuri; Samantha Kimball
Journal:  Endocrine       Date:  2017-10-24       Impact factor: 3.633

Review 10.  The Role of Vitamin D in Thyroid Diseases.

Authors:  Dohee Kim
Journal:  Int J Mol Sci       Date:  2017-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.